In a new analysis at ACC.25, abelacimab reduced bleeding rates across the risk spectrum, with more benefits for those at higher bleeding risk.
Siddharth M. Patel, MD, MPH
Advertisement
Siddharth M. Patel, MD, MPH, is a TIMI Study Group Investigator, Associate Physician in the Cardiovascular Division at Brigham and Women’s Hospital, and Instructor of Medicine at Harvard Medical School.
Articles by Siddharth M. Patel, MD, MPH
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
SimpleScreen CRC Blood Test Meets Endpoints in Clinical Validation Study
2
Liver Lineup: Bepirovirsen and the Push Toward Functional Cure in Hepatitis B
3
Eplontersen Misses Primary Endpoint in Phase 3 ATTR-CM Trial
4
Biologic Therapy for Asthma and COPD: Real-World Perspectives From APPs
5